YU89503A - Korišćenje osteopontina za lečenje i/ili prevenciju neuroloških bolesti - Google Patents
Korišćenje osteopontina za lečenje i/ili prevenciju neuroloških bolestiInfo
- Publication number
- YU89503A YU89503A YU89503A YUP89503A YU89503A YU 89503 A YU89503 A YU 89503A YU 89503 A YU89503 A YU 89503A YU P89503 A YUP89503 A YU P89503A YU 89503 A YU89503 A YU 89503A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- osteopontin
- prevention
- treatment
- neurologic diseases
- neurologic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Psychology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
Abstract
Pronalazak se odnosi na upotrebu osteopontina, ili agonista osteopontinske aktivnosti, za lečenje ili prevenciju neuroloških bolesti.[The invention relates to the use of osteopontin, or of an agonist of osteopontin activity, for treatment or prevention of a neurologic diseases.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01111296 | 2001-05-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
YU89503A true YU89503A (sh) | 2006-05-25 |
Family
ID=8177366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YU89503A YU89503A (sh) | 2001-05-17 | 2002-05-08 | Korišćenje osteopontina za lečenje i/ili prevenciju neuroloških bolesti |
Country Status (27)
Country | Link |
---|---|
US (4) | US7217687B2 (sh) |
EP (1) | EP1389130B1 (sh) |
JP (2) | JP4417632B2 (sh) |
KR (1) | KR100947424B1 (sh) |
CN (2) | CN1286524C (sh) |
AT (1) | ATE555803T1 (sh) |
AU (1) | AU2002312886B2 (sh) |
BG (1) | BG108337A (sh) |
BR (1) | BR0209812A (sh) |
CA (1) | CA2443964A1 (sh) |
CZ (1) | CZ20033109A3 (sh) |
EA (1) | EA006655B1 (sh) |
EE (1) | EE200300559A (sh) |
ES (1) | ES2387082T3 (sh) |
HK (1) | HK1067051A1 (sh) |
HR (1) | HRP20030840A2 (sh) |
HU (1) | HUP0400005A3 (sh) |
IL (2) | IL158867A0 (sh) |
MX (1) | MXPA03010327A (sh) |
NO (1) | NO20035025L (sh) |
NZ (1) | NZ528852A (sh) |
PL (1) | PL211763B1 (sh) |
SK (1) | SK14232003A3 (sh) |
UA (1) | UA85368C2 (sh) |
WO (1) | WO2002092122A2 (sh) |
YU (1) | YU89503A (sh) |
ZA (1) | ZA200307956B (sh) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10291986D2 (de) * | 2001-05-09 | 2004-04-15 | Biovision Ag | Verfahren zum Nachweis einer progredienten, chronisch-demenziellen Erkrankung, zugehörige Peptide und Nachweisreagenzien |
WO2003046135A2 (en) * | 2001-11-21 | 2003-06-05 | The Board Of Trustees Of The Leland Stanford Junior University | Osteopontin-related compositions and methods |
JP2005535313A (ja) * | 2002-06-25 | 2005-11-24 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | オステオポンチン、オリゴデンドロサイトおよび髄鞘形成 |
AU2003258127A1 (en) * | 2002-08-06 | 2004-02-23 | Diadexus, Inc. | Compositions and methods relating to ovarian specific genes and proteins |
KR20050119149A (ko) * | 2003-03-28 | 2005-12-20 | 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. | 말초 신경 질환의 치료 및/또는 예방을 위한 클루스테린의용도 |
EP1667537B1 (en) * | 2003-09-18 | 2013-11-06 | Arla Foods Amba | Infant formula |
CA2546077C (en) | 2003-11-12 | 2016-07-05 | Yeda Research And Development Co. Ltd. | Vaccine and method for treatment of neurodegenerative diseases |
US20060264371A1 (en) * | 2005-02-18 | 2006-11-23 | Proximagen Ltd. | Treatment |
EP1848453B1 (en) * | 2005-02-18 | 2010-10-27 | Proximagen Ltd. | Treatment for neurodegeneration |
JP5203212B2 (ja) | 2005-10-13 | 2013-06-05 | アントフロゲネシス コーポレーション | 胎盤由来幹細胞からのオリゴデンドロサイトの産生 |
EP1870107A1 (en) * | 2006-06-23 | 2007-12-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of inducer of promyelocytic leukemia protein (PML) for treating polyglutamine expansion neurodegenerative diseases |
WO2008086449A2 (en) * | 2007-01-09 | 2008-07-17 | Oregon Health & Science University | Synthetic osteopontin peptides and methods of use |
US20100069254A1 (en) * | 2008-09-16 | 2010-03-18 | Laree Hiser | Cell Culture Model for Demyelination/Remyelination |
KR101449100B1 (ko) | 2011-04-21 | 2014-10-13 | 가톨릭대학교 산학협력단 | 신경세포 데브리스 제거용 오스테오폰틴 |
GB2493540A (en) * | 2011-08-10 | 2013-02-13 | Follicum Ab | Agents for stimulating hair growth in mammals |
WO2014051398A1 (ko) * | 2012-09-28 | 2014-04-03 | 한국생명공학연구원 | 아세카이니드 또는 이의 유도체를 포함하는 근력약화 관련 질환의 예방 또는 치료용 약학적 조성물 |
CA2957958C (en) * | 2014-08-27 | 2023-10-17 | Harvey Cantor | Intracellular osteopontin regulates the lineage commitment of lymphoid subsets |
US11058720B2 (en) | 2016-05-20 | 2021-07-13 | Cedars-Sinai Medical Center | Methods of treating or preventing alzheimer's disease and associated conditions |
CN109996810B (zh) * | 2016-11-27 | 2023-08-22 | 特里同阿盖亚创新公司 | 从微藻中纯化重组骨桥蛋白的方法 |
JP2020518556A (ja) | 2017-05-04 | 2020-06-25 | フォリクム エービー | 糖尿病の処置のためのペプチド |
WO2019036331A1 (en) * | 2017-08-15 | 2019-02-21 | The Children's Medical Center Corporation | OSTEOPONTIN AS A TREATMENT OF NEURONAL INJURIES |
TR201903865A2 (tr) * | 2019-03-14 | 2020-09-21 | Bogazici Ueniversitesi | Amyotrofi̇k lateral skleroz tedavi̇si̇ i̇çi̇n i̇nterferon kullanimi |
WO2021024265A1 (en) * | 2019-08-08 | 2021-02-11 | Ramot At Tel-Aviv University Ltd. | Methods of treating non-infectious inflammatory disorders |
CN111388654A (zh) * | 2020-05-22 | 2020-07-10 | 南通大学 | 治疗脊髓损伤的药物、药物试剂盒及方法 |
EP4159223A4 (en) * | 2020-06-02 | 2024-07-17 | Catholic Univ Korea Ind Academic Cooperation Foundation | COMPOSITION WITH OSTEOPONTIN INHIBITOR AS ACTIVE INGREDIENT FOR THE PREVENTION, RELIEF OR TREATMENT OF NEURODEGENERATIVE DISEASES |
CN117720620B (zh) * | 2023-12-13 | 2024-07-23 | 无锡市儿童医院 | 小分子多肽和其药物组合物、其制药用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1140173T4 (da) * | 1998-12-22 | 2013-06-10 | Genentech Inc | Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf |
AU773350B2 (en) * | 1999-04-15 | 2004-05-20 | Children's Medical Center Corporation | Methods and compositions for modulating an immune response |
WO2000064460A2 (en) | 1999-04-23 | 2000-11-02 | Sulzer Orthopedics Ltd. | Composition for enhancing functional recovery of a mammal from central and/or peripheral nervous system injury of traumatic or pathological origin |
CA2385533C (en) * | 1999-10-04 | 2008-03-25 | Shearwater Corporation | Polymer stabilized neuropeptides |
-
2002
- 2002-05-08 UA UA20031110269A patent/UA85368C2/ru unknown
- 2002-05-08 NZ NZ528852A patent/NZ528852A/en not_active IP Right Cessation
- 2002-05-08 MX MXPA03010327A patent/MXPA03010327A/es active IP Right Grant
- 2002-05-08 ES ES02738042T patent/ES2387082T3/es not_active Expired - Lifetime
- 2002-05-08 PL PL367065A patent/PL211763B1/pl not_active IP Right Cessation
- 2002-05-08 AT AT02738042T patent/ATE555803T1/de active
- 2002-05-08 WO PCT/EP2002/005081 patent/WO2002092122A2/en active Application Filing
- 2002-05-08 AU AU2002312886A patent/AU2002312886B2/en not_active Ceased
- 2002-05-08 SK SK1423-2003A patent/SK14232003A3/sk unknown
- 2002-05-08 KR KR1020037014773A patent/KR100947424B1/ko not_active IP Right Cessation
- 2002-05-08 CN CNB028144627A patent/CN1286524C/zh not_active Expired - Fee Related
- 2002-05-08 JP JP2002589038A patent/JP4417632B2/ja not_active Expired - Fee Related
- 2002-05-08 EP EP02738042A patent/EP1389130B1/en not_active Expired - Lifetime
- 2002-05-08 EE EEP200300559A patent/EE200300559A/xx unknown
- 2002-05-08 CZ CZ20033109A patent/CZ20033109A3/cs unknown
- 2002-05-08 HU HU0400005A patent/HUP0400005A3/hu unknown
- 2002-05-08 CA CA002443964A patent/CA2443964A1/en not_active Abandoned
- 2002-05-08 YU YU89503A patent/YU89503A/sh unknown
- 2002-05-08 CN CNA2006101317669A patent/CN1939538A/zh active Pending
- 2002-05-08 US US10/477,876 patent/US7217687B2/en not_active Expired - Fee Related
- 2002-05-08 BR BR0209812-1A patent/BR0209812A/pt not_active IP Right Cessation
- 2002-05-08 IL IL15886702A patent/IL158867A0/xx unknown
- 2002-05-08 EA EA200301253A patent/EA006655B1/ru not_active IP Right Cessation
-
2003
- 2003-10-13 ZA ZA200307956A patent/ZA200307956B/en unknown
- 2003-10-15 HR HR20030840A patent/HRP20030840A2/hr not_active Application Discontinuation
- 2003-11-10 BG BG108337A patent/BG108337A/bg unknown
- 2003-11-12 NO NO20035025A patent/NO20035025L/no not_active Application Discontinuation
- 2003-11-13 IL IL158867A patent/IL158867A/en not_active IP Right Cessation
-
2004
- 2004-11-05 US US10/981,737 patent/US7297099B2/en not_active Expired - Fee Related
- 2004-12-22 HK HK04110138A patent/HK1067051A1/xx not_active IP Right Cessation
-
2007
- 2007-02-27 US US11/679,735 patent/US20070225214A1/en not_active Abandoned
- 2007-11-07 US US11/936,623 patent/US20080213234A1/en not_active Abandoned
-
2009
- 2009-06-05 JP JP2009136621A patent/JP5036761B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
YU89503A (sh) | Korišćenje osteopontina za lečenje i/ili prevenciju neuroloških bolesti | |
ZA200204020B (en) | Use of anti-CTLA-4-antibodies. | |
HK1078266A1 (en) | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same | |
AP2004003002A0 (en) | azabicyclic-substituted fused-heteroaryl compoundsfor the treatment of disease. | |
WO2004028454A3 (en) | 1, 3, 5-triazines for treatment of viral diseases | |
ZA200501288B (en) | Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma. | |
WO2003088748A8 (en) | Use of heme oxygenase-1 and products of heme degradation | |
ZA200306232B (en) | Treatment involving DKK-1 or antagonists thereof. | |
EP1499309A4 (en) | PREVENTION AND TREATMENT OF FUNCTIONAL SOMATIC DISEASES, INCLUDING STRESS-BASED DISEASES | |
MXPA03008582A (es) | Agentes y metodos para tratamiento de cancer. | |
MXPA05010414A (es) | Uso de clusterina para el tratamiento y/o prevencion de enfermedades neurologicas perifericas. | |
IL161501A0 (en) | Methods of preventing and treating flavivirus infection in animals | |
ZA200205098B (en) | Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2-mediated disorders. | |
WO2004037168A3 (en) | Treatment of pancreatitis with amylin | |
HUP0302738A2 (hu) | SARP-1 alkalmazása scleroderma kezelésére és megelőzésére | |
ZA200004363B (en) | Treatment or prevention of coccidiosis. | |
IL181713A0 (en) | Use of il-17f for the treatment and/or prevention of neurological diseases | |
WO2003096877A3 (en) | Prevention and treatment of streptococcal and staphylococcal infection | |
IL158967A0 (en) | Identifying parasitic fungi of the organism, and treatment thereof | |
WO2003064394A8 (de) | 5-ring heterozyklen zur verwendung als antiviral mittel | |
AU2003287513A1 (en) | INHIBITORS OF Beta-SECRETASE, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF ALZHEIMER'S DISEASE OR MILD COGNITIVE IMPAIRMENT | |
AU2003278569A8 (en) | Methods for identifying antimicrobial agents, the agents identified therewith and methods of using same | |
YU80003A (sh) | Upotreba proteina uk114 ili njegovih fragmenata za tretman i prevenciju endotoksičnog šoka | |
AU2003298547A8 (en) | 2,4,6-triaminopyrimidines for the treatment of depression and/or anxiety | |
AU2002242488A1 (en) | Agents for the prevention and treatment of sexually transmitted diseases -ii |